

**Translation from original French**

**COVID-19  
Activity continuation plan  
Information for the Chief Pharmaceutical Officers, Delegate Chief  
Pharmaceutical Officers and Acting Chief Pharmaceutical Officers**

**The Council of Section B has consulted the ANSM – the French National Agency for the Safety of Medicines and Healthcare Products – in order to answer your questions**

**WHY**

An appeal for the **mobilisation, forward planning, pro-activity and increased vigilance of the Chief Pharmaceutical Officers and their teams** throughout the pharmaceutical chain in order to ensure **continuity of operations** and **continuous, appropriate supply of medicines**.

**Within the framework of confinement, the activity of pharmaceutical companies remains vital.**

The pharmaceutical establishments authorised for the activities of manufacturer, “exploitant”, wholesale importer and distributor must maintain their activity in the interests of patients infected by COVID-19 or by any other chronic or acute pathology requiring treatment with medicines.

**WHAT**

**Activity continuity plan: decisions/risk management**

- **Presence**, actual control: provide for adaptation, flexibility, give priority to working from home, where possible.
- Concentrate on essential **operations** and, where possible, postpone others,
- **Monitor** sales and stock levels, strengthen them where necessary for essential products.
- Ensure employee **safety**.

**Inform** the ANSM of:

- Any **change in organisation** impacting the continuity of pharmaceutical operations,
- Any difficulty in the performance of professional duties.

**Report and declare to** the ANSM, in advance:

- **Risks of breaks in the supply of Medicines of Major Therapeutic Interest**,
- **Unusual sales** or any negative trend in the level of back-up stocks of Medicines of Major Therapeutic Interest.

**HOW**

**Observe the usual procedures for declaration, reporting and information** in respect of the ANSM, highlighting the link to COVID-19

*For the continuity of supply of Medicines of Major Therapeutic Interest: [rupture-stock@ansm.sante.fr](mailto:rupture-stock@ansm.sante.fr)*

*For the operation of pharmaceutical activity: [ipplf@ansm.sante.fr](mailto:ipplf@ansm.sante.fr)*

*The messages must be identified “COVID-19”.*

**The Counsellors of Section B of the French National Order of Pharmacists remain at the disposal of their fellow pharmacists and invite them to regularly consult official sources of information.**

<http://www.ordre.pharmacien.fr/>

<https://www.ansm.sante.fr/>

<https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/>

<https://dgs-urgent.sante.gouv.fr/>